Influenza virus encoding a truncated ns1 protein and a sars-cov receptor binding domain
AssigneeVivaldi Biosciences Inc.
InventorsAmy ASPELUND, Thomas MUSTER, Markus WOLSCHEK
Life of this patent
Estimating the term…
Abstract
The present invention refers to a recombinant influenza vims encoding a fusion protein comprising a truncated NS1 protein and a SARS-CoV receptor binding domain, specifically a SARS-CoV-2 RBD, and its use for prophylactic treatment, a pharmaceutical preparation comprising said virus for use in prime boost vaccination and a two-component vaccine for prime boost vaccination.
Claims23
A recombinant influenza virus comprising a modified NS segment, encoding:
- a) a fusion protein comprising from N to C-terminus:
- a truncated NS1 protein consisting of 10 to 20 amino acids of the N-terminus of the respective wild type NS1 protein,
- optionally a linker sequence,
- optionally a 2A self-cleaving peptide, specifically a P2A sequence,
- a signal peptide,
- a SARS-CoV receptor binding domain (RBD), optionally comprising additional 10 to 50 amino acids of the SARS-CoV S1 subunit at its C-terminus, and
- b) an NS2 protein.
(canceled)
The recombinant influenza virus claim 11, wherein the virus is present in the pharmaceutical preparation in an effective amount.
23-24. (canceled)
Dependencies are inferred from the claim text.